Summary
Stryker Corporation (SYK) announced on May 16, 2011, that it has entered into a definitive agreement to acquire Orthovita, Inc. via an all-cash tender offer. This strategic move positions Stryker to enhance its product portfolio and market presence within the orthopedics sector. The acquisition of Orthovita is valued at approximately $316 million, considering Orthovita's fully diluted shares outstanding and its net debt. Shareholders of Orthovita will receive $3.85 in cash for each share of common stock they hold. The transaction is contingent upon regulatory approvals, specifically the expiration or termination of waiting periods under the Hart-Scott-Rodino Antitrust Improvements Act, along with other standard closing conditions.
Key Highlights
- 1Stryker Corporation (SYK) to acquire Orthovita, Inc. through an all-cash tender offer.
- 2Transaction value estimated at $316 million.
- 3Orthovita shareholders to receive $3.85 per share in cash.
- 4Acquisition aims to strengthen Stryker's position in the orthopedics market.
- 5Transaction is subject to customary closing conditions, including antitrust review (Hart-Scott-Rodino Act).
- 6The deal was announced on May 16, 2011.
Frequently Asked Questions
The acquisition of Orthovita, Inc. is intended to enhance Stryker's product offerings and strengthen its competitive position within the orthopedics industry.
The total estimated value of the transaction is $316 million, which includes the cash payment for Orthovita's shares and its net debt.
Orthovita shareholders will receive $3.85 in cash for each share of Orthovita common stock they own.
Yes, the transaction is subject to standard closing conditions, including the expiration or termination of waiting periods under the Hart-Scott-Rodino Antitrust Improvements Act, and other customary conditions.